Weekly injections of semaglutide to assess energy expenditure in obese patients
The Effect of Weekly Semaglutide Treatment on Energy Expenditure
This study is testing if weekly injections of semaglutide can help obese patients burn more energy and improve their metabolism while they follow a calorie-restricted diet.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 60 Years |
| Sex | Female |
| Sponsor | Shenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences Academic / other |
| Locations | 1 site (Shenzhen) |
| Trial ID | NCT06390501 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effects of weekly semaglutide injections on energy expenditure and metabolic parameters over a 24-week period. It is a double-blind, placebo-controlled, dose escalation randomized trial involving 52 participants who will follow a calorie-restricted diet while receiving either semaglutide or a placebo. The study aims to evaluate changes in weight status, body composition, basal metabolic rate, and energy expenditure, among other metabolic factors, before and after treatment. The findings could provide insights into the effectiveness of semaglutide in managing obesity and its related metabolic issues.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18-60 with a BMI of 25 kg/m² or higher.
Not a fit: Patients who have experienced significant weight changes recently or have a history of certain metabolic diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could lead to improved weight management and metabolic health for patients with obesity.
How similar studies have performed: Previous studies using GLP-1 receptor agonists have shown promising results in weight loss and metabolic control, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria: 1. Age 18-60 years at time of enrollment 2. BMI ≥ 25 kg/m² Exclusion criteria: 1. Weight change exceeding 5 kilograms (11 pounds) in the past 90 days 2. Surgical treatment for past obesity, dieting, or undergoing weight loss treatment 3. Irregular diet and lifestyle, unhealthy habits such as smoking, alcohol, and drugs 4. Patients with metabolic diseases, basic diseases or infectious diseases 5. Patients with a personal or family history of medullary thyroid carcinoma (MTC), or patients with rare type 2 multiple endocrine tumor syndrome (MEN 2) 6. Current use of any other GLP1 receptor agonist 7. Pregnancy, lactation or expectation to conceive during study period (8) Subject with contraindication to neuroimaging by MRI (9) People with fear of blood and pathologically low blood pressure (10) Use of antibiotics and probiotics within 8 weeks 11) Subject unlikely to adhere to study procedures in opinion of investigator
Where this trial is running
Shenzhen
- Shenzhen Institute of Advanced Technology — Shenzhen, China (Recruiting)
Study contacts
- Study coordinator: John R Speakman, phD
- Email: j.speakman@abdn.ac.uk
- Phone: 13466654659
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.